TY - JOUR T1 - Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents JO - Anales de Pediatría (English Edition) T2 - AU - Quintero,Jesús AU - Juampérez,Javier AU - Julio,Ecaterina AU - Cabello,Vanessa AU - Mercadal-Hally,Maria AU - Soler-Palacín,Pere AU - Segarra,Óscar AU - Rodrigo,Carlos SN - 23412879 M3 - 10.1016/j.anpede.2018.07.004 DO - 10.1016/j.anpede.2018.07.004 UR - https://analesdepediatria.org/en-ledipasvir-sofosbuvir-combination-for-chronic-hepatitis-articulo-S2341287919300079 AB - IntroductionThe aim of this study was to assess the safety and efficacy of ledipasvir/sofosbuvir combination in chronic Hepatitis C Virus (HCV) genotype 1 and 4 infection in paediatric patients. MethodsEligible patients to be treated with ledipasvir/sofosbuvir were patients from 6 to 18 years old with a chronic HCV genotype 1 or 4 infection. The duration and doses of antiviral drugs were changed depending on patient age, fibrosis stage, and PEGylated interferon+ribavirin experience status. The primary efficacy endpoint was the percentage of patients with a sustained virological response 12 weeks posttreatment. ResultsA total of nine patients (7 males) with a median age of 14.8 years (8.48–17.91) were treated with ledipasvir/sofosbuvir combination. Five patients received previous treatment with PEGylated interferon+ribavirin during a median of 8.5 months (3–12 months). Eight patients had some degree of fibrosis (1 patient presented with F1, three patients F2, 2 patients F3, and 2 patients F4). The median pre-treatment viral load was 6.2log [5.9–6.8] with the HCV RNA becoming negative six weeks after starting the treatment in 100% of the patients. All patients maintained a sustained viral response at 12 weeks. Three patients (33.3%) had some type of adverse effect (2 headache and one oral thrush). The median posttreatment follow-up was 24 weeks (12–104). ConclusionsTreatment with ledipasvir/sofosbuvir in paediatric patients with chronic HCV infection genotype 1 and 4 is safe and effective with SVR12 and similar to those reported in adults. ER -